2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P4146
    Survodutide 2805997-46-8 99.92%
    Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake.
    Survodutide
  • HY-101981
    Uridine 5'-monophosphate 58-97-9
    Uridine 5'-monophosphate (5'-Uridylic acid) is an orally active mitochondrial ATP-dependent potassium channel activator that has a protective effect on the heart. Uridine 5'-monophosphate can promote the synthesis of CDP-choline and induce apoptosis in intestinal epithelial cells, which is beneficial for gut development and reduces diarrhea.
    Uridine 5'-monophosphate
  • HY-142114
    SRI-37330 2322245-42-9 99.16%
    SRI-37330 is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 can be used for type 2 diabetes research.
    SRI-37330
  • HY-B1232
    Metyrapone 54-36-4 99.84%
    Metyrapone (Su-4885) is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone can be used for researching Cushing's syndrome and depression.
    Metyrapone
  • HY-50663
    MK 0893 870823-12-4 99.86%
    MK 0893 is a potent and selective glucagon receptor antagonist with an IC50 of 6.6 nM.
    MK 0893
  • HY-N2364
    Arecoline 63-75-2 99.84%
    Arecoline, a naturally occurring psychoactive alkaloid, is a partial agonist of nicotinic and muscarinic acetylcholine receptor. Arecoline exhibits stimulation, alertness, anxiolysis and anti-parasitic effects. Arecoline also can induce oxidative stress.
    Arecoline
  • HY-13749A
    Sitagliptin phosphate 654671-78-0 99.79%
    Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts.
    Sitagliptin phosphate
  • HY-B0401
    Tolbutamide 64-77-7 ≥98.0%
    Tolbutamide is an orally active KATP inhibitor. Tolbutamide inhibits cell proliferation, stimulates exocytosis of glucagon and reduces fetal lethality of mice. Tolbutamide can be used in the research of diabete.
    Tolbutamide
  • HY-B1058
    Benfluorex hydrochloride 23642-66-2 99.85%
    Benfluorex hydrochloride (JP-992 hydrochloride) is a hepatic nuclear factor 4 alpha (HNF4α) activator.
    Benfluorex hydrochloride
  • HY-N4103
    Fucosterol 17605-67-3 ≥98.0%
    Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities. Fucosterol regulates adipogenesis via inhibition of PPARα and C/EBPα expression and can be used for anti-obesity agents development research.
    Fucosterol
  • HY-125783
    1-Palmitoyl-sn-glycero-3-phosphocholine 17364-16-8 ≥98.0%
    1-Palmitoyl-sn-glycero-3-phosphocholine is an abundant lysophosphatidylcholine. 1-Palmitoyl-sn-glycero-3-phosphocholine exhibits proinflammatory activity. 1-Palmitoyl-sn-glycero-3-phosphocholine can be used in the study of atherosclerosis.
    1-Palmitoyl-sn-glycero-3-phosphocholine
  • HY-148476
    Tri-GalNAc-DBCO 99.92%
    Tri-GalNAc-DBCO is a synthetic ligand composed of three GalNAc units linked to DBCO. Tri-GalNAc-DBCO can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing an azide group. Tri-GalNAc-DBCO specifically binds to the asialoglycoprotein receptor (ASGPR). Tri-GalNAc-DBCO directs the conjugated molecule to the lysosome for degradation via receptor-mediated endocytosis. Tri-GalNAc-DBCO can be used in the study of liver-related diseases.
    Tri-GalNAc-DBCO
  • HY-111174
    Diprotin A 90614-48-5 99.58%
    Diprotin A (Ile-Pro-Ile) is an inhibitor of dipeptidyl peptidase IV (DPP-IV).
    Diprotin A
  • HY-113416
    Dehydroepiandrosterone sulfate 651-48-9 99.93%
    Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate has both non-competitive antagonist activity of GABAA receptor and agonist activity of σ1 receptor. Dehydroepiandrosterone sulfate can partially penetrate the blood-brain barrier, inhibit GABAA receptor-mediated chloride influx, enhance NMDA receptor activity through σ1 receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality.
    Dehydroepiandrosterone sulfate
  • HY-120691A
    GSK205 1263068-83-2 99.47%
    GSK205 is a potent, selective TRPV4 antagonist with an IC50 of 4.19  μM for inhibiting TRPV4-mediated Ca2+ influx.
    GSK205
  • HY-12377
    GSK0660 1014691-61-2 99.49%
    GSK0660 is a potent PPARβ antagonist with an IC50 of 155 nM.
    GSK0660
  • HY-D0227
    THAM 77-86-1 ≥98.0%
    THAM (Tris) is a biologically inert amino alcohol of low toxicity, which buffers carbon dioxide and acids in vitro and in vivo. THAM is an effective amine compound for pH control in the physiological range.
    THAM
  • HY-N0395
    Fructose 7660-25-5 ≥98.0%
    Fructose is a simple ketonic monosaccharide found in many plants, where it is often bonded to glucose to form the disaccharide sucrose.
    Fructose
  • HY-110267
    DY268 1609564-75-1 99.32%
    DY268 is a farnesoid X receptor (FXR) antagonist (IC50=7.5 nM). It inhibits FXR transactivation in a cell-based assay with an IC50 value of 468 nM. DY268 can be used in the study of drug-induced liver injury (DILI).
    DY268
  • HY-101903A
    BMS-309403 sodium 2802523-05-1 99.93%
    BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells.
    BMS-309403 sodium
Cat. No. Product Name / Synonyms Application Reactivity